

Richard A Franklin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7324105/richard-a-franklin-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

4,776
citations

26
h-index

58
g-index

58
ext. papers

5,162
ext. citations

5.1
avg, IF

4.61
L-index

#	Paper	IF	Citations
55	Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.. <i>Aging</i> , 2022 , 14, 3365-3386	5.6	0
54	Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3944-57	3.3	42
53	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. <i>Advances in Biological Regulation</i> , 2013 , 53, 146-55	6.2	14
52	Novel approaches to target cancer initiating cells-eliminating the root of the cancer. <i>Advances in Biological Regulation</i> , 2012 , 52, 249-64	6.2	13
51	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. <i>Oncotarget</i> , 2012 , 3, 1068-111	3.3	250
50	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , 2012 , 11, 4447-61	4.7	21
49	Advances in targeting signal transduction pathways. <i>Oncotarget</i> , 2012 , 3, 1505-21	3.3	39
48	Targeting the cancer initiating cell: the AchillesSheel of cancer. <i>Advances in Enzyme Regulation</i> , 2011 , 51, 152-62		13
47	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. <i>Cell Cycle</i> , 2011 , 10, 3003-15	4.7	71
46	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. <i>Oncotarget</i> , 2011 , 2, 135-64	3.3	456
45	Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. <i>Oncotarget</i> , 2011 , 2, 538-50	3.3	69
44	A multipronged approach to prostate cancer. <i>Cancer Biology and Therapy</i> , 2008 , 7, 594-5	4.6	
43	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. <i>Advances in Enzyme Regulation</i> , 2008 , 48, 113-35		20
42	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy 2008 , 81-114		
41	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007 , 1773, 1263-84	4.9	1532
40	Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. <i>Advances in Enzyme Regulation</i> , 2007 , 47, 64-103		63
39	17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 618-32	6.1	28

38	Polyphenols in breast cancer treatment. <i>Cancer Biology and Therapy</i> , 2007 , 6, 62-3	4.6	
37	Critical Roles of the Raf/MEK/ERK Pathway in Apoptosis and Drug Resistance 2006 , 101-134		2
36	EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. <i>Cell Cycle</i> , 2006 , 5, 2820-6	4.7	56
35	Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1022-30	4.6	25
34	OSU-03012 in the treatment of glioblastoma. <i>Molecular Pharmacology</i> , 2006 , 70, 437-9	4.3	15
33	Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. <i>Antioxidants and Redox Signaling</i> , 2006 , 8, 1807-17	8.4	36
32	Reactive oxygen species-induced activation of the MAP kinase signaling pathways. <i>Antioxidants and Redox Signaling</i> , 2006 , 8, 1775-89	8.4	588
31	Molecular pathways leading to oxidative stress-induced phosphorylation of Akt. <i>Antioxidants and Redox Signaling</i> , 2006 , 8, 1749-56	8.4	39
30	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. <i>Advances in Enzyme Regulation</i> , 2006 , 46, 249-79		518
29	Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line. <i>Cell Cycle</i> , 2005 , 4, 818-21	4.7	9
28	Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2005 , 9, 791-808	6.4	27
27	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?. <i>Expert Opinion on Therapeutic Targets</i> , 2005 , 9, 1009-30	6.4	45
26	Inhibition of CREB transcriptional activity in human T lymphocytes by oxidative stress. <i>Free Radical Biology and Medicine</i> , 2005 , 38, 1653-61	7.8	10
25	Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. <i>Cancer Research</i> , 2005 , 65, 5408-16	10.1	60
24	Two targets are better than one. Promising combination therapy to treat breast cancer. <i>Cancer Biology and Therapy</i> , 2005 , 4, 1190-1	4.6	1
23	Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. <i>Cell Cycle</i> , 2005 , 4, 822-30	4.7	25
22	B-Raf and Insulin Synergistically Prevent Apoptosis and Induce Cell Cycle Progression in Hematopoietic Cell. <i>Cell Cycle</i> , 2004 , 3, 184-191	4.7	3
21	Redox regulation of the calcium/calmodulin-dependent protein kinases. <i>Journal of Biological Chemistry</i> , 2004 , 279, 44573-81	5.4	105

20	Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. <i>Oncogene</i> , 2004 , 23, 7810-20	9.2	19
19	B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. <i>Cell Cycle</i> , 2004 , 3, 189-96	4.7	7
18	Models of energy in the human Jurkat T cell line. <i>Assay and Drug Development Technologies</i> , 2003 , 1, 537-44	4.4	8
17	Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. <i>Oncogene</i> , 2003 , 22, 2478-92	9.2	92
16	The use of the yeast two-hybrid system to measure protein-protein interactions that occur following oxidative stress. <i>Methods in Molecular Biology</i> , 2003 , 218, 47-57	1.4	
15	Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced I κ B phosphorylation in human T lymphocytes. <i>Journal of Biological Chemistry</i> , 2002 , 277, 30469-76	5.4	49
14	Regulation of Pyk2 expression by p56(Lck) in Jurkat T lymphocytes. <i>Cellular Signalling</i> , 2001 , 13, 65-9	4.9	8
13	Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. <i>Advances in Enzyme Regulation</i> , 2001 , 41, 289-323		18
12	A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. <i>Oncogene</i> , 2000 , 19, 526-36	9.2	73
11	T cell receptor assembly and expression in the absence of calnexin. <i>Archives of Biochemistry and Biophysics</i> , 2000 , 378, 182-9	4.1	10
10	Oxidative stress regulates the interaction of p16 with Cdk4. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 275, 764-7	3.4	13
9	Calcium-induced ERK activation in human T lymphocytes occurs via p56(Lck) and CaM-kinase. <i>Molecular Immunology</i> , 2000 , 37, 675-83	4.3	53
8	Human CD45RA+ and CD45RO+ T cells exhibit similar CD3/T cell receptor-mediated transmembrane signaling capacities but differ in response to co-stimulatory signals. <i>European Journal of Immunology</i> , 1994 , 24, 1391-5	6.1	20
7	Macrophages suppress lectin-induced proliferation of lymphocytes from aged rats. <i>Mechanisms of Ageing and Development</i> , 1993 , 67, 33-46	5.6	27
6	Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 186, 1315-21	3.4	62
5	Signal transduction by interleukin 2 in human T cells: activation of tyrosine and ribosomal S6 kinases and cell-cycle regulatory genes. <i>Journal of Cellular Physiology</i> , 1992 , 151, 367-77	7	25
4	The proliferative response of rat T cells to calcium ionophores increases with age. <i>Cellular Immunology</i> , 1990 , 130, 416-28	4.4	12
3	Glutathione augments in vitro proliferative responses of lymphocytes to concanavalin A to a greater degree in old than in young rats. <i>Journal of Nutrition</i> , 1990 , 120, 1710-7	4.1	27

- | | | | |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|
| 2 | A soluble 61-kDa protein is associated with inhibition of lectin-induced proliferation and IL-2 synthesis. <i>Experimental Biology and Medicine</i> , 1987 , 186, 1-12 | 3-7 | 1 |
| 1 | Induction of IL-2 and lymphokine activated killer cells in the cat. <i>Veterinary Immunology and Immunopathology</i> , 1987 , 16, 1-10 | 2 | 33 |